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The marked increases in p53 and p21/WAF1 levels that occur during Epstein–Barr virus (EBV) infection and the generation
of immortal B lymphoblastoid cell lines (LCL) do not lead to growth arrest or apoptosis, although increasing wild-type (wt) p53
levels in EBV-infected cells by transfection or DNA damage induce these effects. We hypothesized that the concentration of
p53 relative to that of LMP1 determines whether EBV-infected B cells undergo growth arrest and apoptosis. Cell cycle arrest
and apoptosis were evaluated in LCL expressing varying p53 levels achieved by treating the cells with increasing
concentrations of cisplatin, and we supplemented this approach with experiments in EBV-infected Burkitt’s lymphoma (BL)
cells transfected with a temperature-sensitive (ts) mutant human p53 and studies in LCL infected with recombinant
adenoviruses expressing wt and ts mutant p53. Small increases in p53 and p21/WAF1 led to cell cycle arrest at the G2/M
boundary, but not to apoptosis; moderate increases resulted in growth arrest at the G1/S boundary, also without apoptosis;
and large increases also induced apoptosis. These results confirm the hypothesis and reveal unanticipated complexities in
cell cycle regulation by p53. © 1998 Academic Press
INTRODUCTION
The protein encoded by the wild-type (wt) p53 gene
possesses potent tumor suppressor functions in vivo.
Evidence for this conclusion comes from the demonstra-
tion that missense mutations leading to inactivation of
the p53 protein, or loss of the gene, represent the most
common genetic abnormality in human malignancies
because they characterize .50% of a large variety of
tumor types (Greenblatt et al., 1994; Hollstein et al., 1991,
1994). Furthermore, mice lacking p53, or expressing mu-
tant p53, exhibit a markedly increased incidence of tu-
mors (Donehower et al., 1992; Lavigueur et al., 1989;
Williams et al., 1994). In addition, several DNA tumor
viruses, including SV40, adenovirus, and human papillo-
mavirus, encode proteins that interact with and inacti-
vate the nuclear protein encoded by the p53 gene (Lech-
ner et al., 1992; Ludlow, 1993; Sarnow et al., 1982). The
mechanisms responsible for the tumor suppressor func-
tions of the p53 gene represent a focus of intense study.
In this regard, in vitro studies have documented a num-
ber of functions for p53 in various cell types, including
regulation of cell cycle progression at the G1/S boundary
(Ginsberg et al., 1991; Hunter, 1993), induction of apopto-
sis (Yonisch-Rouach et al., 1991), transcriptional activa-
tion of various genes involved in cell cycle regulation
(El-Deiry et al., 1993; Harper et al., 1993; Hunter, 1993;
Marx, 1994), and triggering of cellular differentiation
(Aloni-Grinstein et al., 1993; Shaulsky et al., 1991).
We are interested in the mechanisms that enable Ep-
stein–Barr virus (EBV), a DNA tumor virus of the g-her-
pesvirus family, to infect and transform human B cells
and thereby generate permanently dividing immortal lym-
phoblastoid cell lines (LCL) that express a subset of 11
EBV genes, termed latent genes. B cell immortalization
requires that EBV permanently dysregulate the cellular
mechanisms that regulate cell cycle progression and
apoptosis, processes that are p53 dependent in a num-
ber of cell types.
In earlier studies, we observed that de novo infection
of normal B cells with EBV rapidly increased basal p53
levels by ;10-fold (Chen and Cooper, 1996); other inves-
tigators have reported similar findings (Allday et al.,
1995b; Szekely et al., 1995). The increase in p53 levels
was shown to be mediated by the EBV latent cycle
protein, LMP1, via activation of the nuclear factor (NF)-kB
transcription factor (Chen and Cooper, 1996); LMP1, a
membrane protein, possesses oncogenic properties in
certain cell types (Wang et al., 1985). The p53 induced by
EBV infection was wt because it was transcriptionally
active (Allday et al., 1995b; Chen and Cooper, 1996), a
finding that indicates that EBV does not encode a p53-
complexing or -inactivating protein, which is in contrast
to the other DNA tumor viruses noted above.
It is certainly surprising that EBV increases p53 levels
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during the process of immortalizing B lymphocytes be-
cause overexpression of wt p53 in a number of cell types
blocks cell cycle progression at the G1/S boundary and
leads to apoptosis (Lane, 1992; Levine, 1997; Oren, 1992).
This also applies to lymphocytes because expression of
wt p53 in EBV-negative Burkitt’s lymphoma (BL) cell lines
bearing endogenous nonfunctional, mutant p53 resulted
in cell cycle arrest at the G1/S boundary and apoptosis
(Okan et al., 1995; Ramqvist et al., 1993). The induction of
increased levels of p53 in B cells by EBV early in infec-
tion requires that the virus also possess mechanisms to
counteract the potentially lethal properties of the in-
creased concentrations of p53. The EBV membrane pro-
tein LMP1 fulfills this role because it upregulates intra-
cellular levels of bcl-2 and A20, two antiapoptotic pro-
teins (Henderson et al., 1991; Fries et al., 1996; Laherty et
al., 1992). LMP1 also blocks apoptosis triggered by over-
expression of wt p53 in EBV-negative BL cells bearing
mutant p53 (Okan et al., 1995). These actions of LMP1
could clearly be responsible for preventing p53-induced
apoptosis during the process of immortalization, as well
as indefinitely, because LCL also manifest increased p53
levels and express LMP1.
In apparent conflict, however, overexpression of wt
p53 in LCL by transfection blocked cell cycle progression
at the G1/S boundary and induced apoptosis (Allday et
al., 1995a, 1995b). LMP1, which is present in substantial
concentrations in LCL, was clearly unable to block apop-
tosis triggered by transfection with wt p53. Increasing wt
p53 concentrations in LCL by treatment of the cells with
cisplatin, a genotoxic agent, yielded the same results
(Allday et al., 1995a, 1995b).
These discrepant findings in EBV-infected cells can be
reconciled if the concentration of p53 relative to that of
LMP1 in EBV-infected cells determines whether the cells
proceed through the cell cycle and continue to divide or,
alternatively, respond with cell cycle arrest and/or apop-
tosis. The present studies were initiated to evaluate this
hypothesis by further exploring the relationship among
p53 expression, growth arrest, and apoptosis in EBV-
infected cells. Two primary approaches were used. First,
a human p53 temperature-sensitive (ts) mutant
(Val143Ala), which exhibits a mutant nonfunctional con-
formation at 37°C and a transcriptionally active wt con-
formation at 32°C (Baker et al., 1990; Zhang et al., 1994),
was expressed in LCL and in an EBV-negative BL cell
line before and after infection with EBV. Second, varying
levels of wt p53 were systematically induced in LCL by
treatment of the cells with increasing concentrations of
cisplatin. The cells were all evaluated for p53 and p21/
WAF1 levels and for cell cycle arrest and apoptosis. The
findings collectively show that p53 triggered growth ar-
rest and apoptosis is dose dependent in EBV-positive B
cells. They further indicate that small increases in cellu-
lar p53 and p21/WAF1 lead to cell cycle arrest at the
G2/M boundary but not to apoptosis; moderate in-
creases mediate cell cycle arrest at the G1/S boundary,
also without apoptosis, whereas large increases also
induce apoptosis. Finally, they demonstrate that although
EBV proteins expressed in type III latency inhibited p53-
mediated apoptosis, they lacked the ability to block p53-
induced cell cycle arrest at the G1/S or G2/M bound-
aries.
RESULTS
EBV proteins block p53-induced apoptosis in BL and
LCL
BL41, an EBV-negative cell line that endogenously ex-
presses high levels of mutant p53 (Farrell et al., 1991),
was stably transfected with a human p53 ts mutant
(Val143Ala) (Baker et al., 1990; Zhang et al., 1994). This
p53 ts mutant has a mutant conformation at 37°C and a
wt conformation at 32°C (Zhang et al., 1994). Western
blotting analyses revealed a single p53 band at 37°C
and two bands at 32°C (Fig. 1); the faster band was
absent in untransfected cells and in cells transfected
with vector alone and thus likely represents wt p53, with
the faster mobility being due to phosphorylation differ-
ences, as has been described previously (Ullrich et al.,
1992). The mobility difference is not due to polymorphism
at codon 72 because endogenous p53 and the ts mutant
both express arginine at codon 72 (Baker et al., 1990;
Farrell et al., 1991). At 37°C, BL41 cells expressing the
p53 ts mutant, the parent cells, and the cells transfected
with empty vector exhibited identical growth character-
istics (Fig. 2). At 32°C, the p53 ts mutant-bearing cells
died rapidly, with ;50% cell loss occurring 30 h after
placement of the cells at 32°C (Fig. 2). These data are in
agreement with previous studies with BL41 cells trans-
fected with a murine p53 ts mutant (Ala135Val) (Ramqvist
FIG. 1. Expression of p53 in BL41 cells. BL41 cells were stably
transfected with a human p53 ts mutant (Val143Ala) using electropo-
ration. Total cellular extracts (5 3 105 cells) were prepared after 24 h of
growth at 37°C and after various times of growth at 32°C and assessed
for p53 protein in Western blotting studies. The bands designated as a
and b represent p53 with mutant and wt conformations, respectively.
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et al., 1993). Cell death was due to apoptosis, as deter-
mined morphologically, and by DNA fragmentation (not
shown), as previously shown (Ramqvist et al., 1993).
Next, we evaluated the effect of EBV infection on
p53-induced apoptosis in BL41 cells. BL41 cells can be
stably infected with EBV (Calender et al., 1987; Wang et
al., 1990) despite expression of very low levels of the EBV
receptor CD21. EBV infection of BL41 cells yielded type III
EBV infection, with EBNA2 and LMP1 expression levels
comparable to those found in LCL (Fig. 3A). Bcl-2 levels
were also upregulated in EBV-infected BL41 cells (Fig.
3B). EBV infection of the BL41 cells prevented apoptosis
induced by the human p53 ts mutant at the permissive
temperature (Fig. 2), likely via the actions of LMP1, which
has been reported to block p53-mediated apoptosis via
bcl-2 induction (Okan et al., 1995).
The effects of p53 overexpression in LCL were also
evaluated. However, because LCL are difficult to trans-
fect, p53 overexpression was induced by infection with a
recombinant adenovirus containing the human ts p53
mutant. Western blotting analyses showed a 3.5-fold in-
crease in p53 levels, manifested as an increased density
of a single p53 band at either 37°C or 32°C (Fig. 4A). LCL
expressing the human p53 ts mutant were resistant to
apoptosis at either temperature 3 days after adenovirus
infection (Fig. 4B). In other studies, significant apoptosis
did not occur over a 7-day period of observation (not
shown). Because of concern about recombination be-
tween transfected mutant p53 and endogenous wt p53 in
the cells at the permissive temperature, with the as-
sumption of a dominant negative phenotype (Milner and
Medcalf, 1991), LCL were also infected with a recombi-
nant adenovirus containing wt p53. This yielded a 4-fold
increase in p53 levels at both temperatures (Fig. 4A), and
as observed with the p53 ts mutant, the cells were not
susceptible to apoptosis at either temperature (Fig. 4B).
The lack of apoptosis in these studies contrasts with
the report that wt p53 overexpression in LCL induces
apoptosis (Allday et al., 1995b). It is unlikely that the
method used to achieve overexpression of p53 in LCL in
the current studies (i.e., infection with a recombinant
virus compared with transfection with a plasmid contain-
ing an inducible promoter) accounts for the different
results obtained in this and the previous study (Allday et
al., 1995b). We postulated that a critical relationship be-
tween p53 and LMP1 concentrations determines
whether apoptosis occurs and directly addressed this
hypothesis in the cisplatin experiments described below.
FIG. 3. Expression of EBNA2, LMP1, and bcl-2 after infection of
BL41/ts-p53 stable transfectants with EBV. (A) Western blotting analysis
of EBNA2 and LMP expression. (B) Western blotting analysis of bcl-2
expression.
FIG. 2. EBV infection blocks p53-dependent apoptosis in BL41 cells.
Human BL41/ts-p53 stable transfectants and EBV-infected BL41/ts-p53
cells, together with control cells (BL41 and BL41/vector), were grown at
37°C or 32°C and evaluated for viable cells by the MTT assay at the
indicated times.
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EBV proteins do not block p53-induced upregulation
of p21/WAF1 and cell cycle arrest at the G1/S
boundary in BL and LCL
In this study, the effect was evaluated of EBV infection
of BL41 cells on p53-induced induction of p21/WAF1 and
growth arrest. Augmented p21/WAF1 levels were ob-
served in the transfected BL41 cells at the permissive
temperature, and this induction was not altered by EBV
infection (Fig. 5A). Cell cycle analyses carried out 24 h
after placement of the cells at 32°C showed that the p53
ts mutant bearing BL41 cells was arrested at the G1/S
boundary because 71.5% of the cells were in G1 and
27.1% were in the other phases of the cell cycle, which is
in contrast to 55.8% in G1 and 42.1% in S and G2/M
together in the same cells at 37°C (Fig. 5B).
EBV infection had no effect on cell cycle arrest at the
G1/S boundary in the BL41 cells bearing the p53 ts
mutant because 71.5% of the uninfected cells were in G1
and 27.1% were in the other phases of the cell cycle,
whereas 72.7% of the EBV-infected BL41 ts p53 mutant-
bearing cells were in G1 and 25.5% were in S plus G2/M
together at 32°C (Fig. 5B). Therefore, none of the EBV
genes expressed in type III latency possess the ability to
block p53-induced p21/WAF1 expression and cell cycle
arrest at the G1/S boundary. A previous study had shown
that LMP1 lacks this property (Okan et al., 1995), but
other EBV proteins were not assessed. Studies in LCL
yielded data consistent with this interpretation because
p21/WAF1 was induced only at 32°C in LCL infected with
adenovirus containing the human p53 ts mutant, where
the ts mutant exhibits a wt conformation, but the cell
cycle regulatory protein was induced at 32°C, as well as
at 37°C, in LCL infected with adenovirus encoding wt
p53 (Fig. 6A). Cell cycle arrest occurred at the G1/S
boundary in LCL infected with adenovirus containing ts
mutant p53 at 32°C (69.1% in G1 and 29.4% in the other
phases of the cell cycle vs 48.9% in G1 and 47.9% in S
and G2/M together at 37°C). This was also true of LCL
infected with virus-expressing wt p53 at both 32°C
(68.9% in G1 and 29.4% in S plus G2/M) and 37°C (63.5%
in G1 and 35.9% in the other phases of the cell cycle)
(Fig. 6B).
FIG. 5. EBV infection does not interfere with p21/WAF1 induction by
wt 53 or with wt p53-induced growth arrest. BL41/ts-p53 stable trans-
fectants and EBV-infected BL41/ts-p53 cells were grown at 37°C or
32°C for 24 h and then evaluated for p21/WAF1 expression and cell
cycle progression. (A) Western blotting analysis of p21/WAF1 expres-
sion. (B) Flow cytometric analysis of cell cycle status.
FIG. 4. Expression of p53 and apoptosis of LCL expressing wt or ts
mutant p53. LCL were infected with recombinant adenovirus containing
wt or ts mutant p53. After 24 h at 37°C followed by 48 h at either 37°C
or 32°C, the cells were evaluated for p53 expression and apoptosis. (A)
Western blotting analysis of p53 expression. (B) Cell viability analyses.
Viability was determined by the MTT assay.
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The effects of p53 on apoptosis and cell cycle arrest
are dose dependent
The comparative studies in BL and LCL overexpress-
ing p53 described above suggest that p53-mediated
apoptosis and cell cycle arrest are dependent on a critical
relationship between the concentrations of p53 and
LMP1 in the cells. We directly evaluated this hypothesis
by examining p53-induced apoptosis, p21/WAF1 induc-
tion, and cell cycle arrest in cells expressing a range of
concentrations of wt p53. Because of the technical diffi-
culties inherent in achieving varying expression levels of
transfected genes in cells, we evaluated the possibility
that treatment of LCL with increasing cisplatin concen-
trations would yield cells with incremental increases in
endogenous wt p53 levels. This proved to be the case
because treatment of LCL with cisplatin concentrations
between 0.16 and 20 mg/ml for 18 h yielded LCL with
increasing p53 concentrations that ranged from ;1.2-fold
to 12-fold over endogenous levels (Table 1, Fig. 7). LMP1
levels in the cells were only modestly reduced by treat-
ment with cisplatin (0.4-fold decrease at 20 mg/ml cis-
platin) (Fig. 8). Interestingly, the LCL were resistant to
apoptosis when treated with cisplatin concentrations of
,5.0 mg/ml, which were associated with p53 levels up to
;5.4-fold above the endogenous concentration (Table 1).
Treatment with 5 mg/ml cisplatin produced an ;10-fold
increase in the p53 concentration and resulted in 30%
apoptosis, whereas 10 mg/ml cisplatin yielded an ;15.6-
fold increase in p53 levels and 55% apoptosis (Table 1).
FIG. 6. Overexpression of wt and ts mutant p53 in JR LCL by
adenovirus delivery leads to p21/WAF1 upregulation and growth arrest.
LCL were infected with recombinant adenoviruses containing wt or ts
mutant p53 and evaluated for p21/WAF1 expression and cell cycle
progression after 24 h at 37°C followed by 48 at 32°C. (A) Western
blotting analysis of p21/WAF1 expression. (B) Flow cytometric analysis
of cell cycle status.
TABLE 1
Consequences of Treatment of JR LCL with Cisplatin
Cisplatin concentration (mg/ml) 0.0 0.16 0.32 0.63 1.25 2.5 5.0 10.0 20.0
Apoptotic cells (%) 0.0 0.0 0.0 2.0–3.0 5.0 5.0–10.0 30.0 55.0 90.0
p53 induction (approximate) 1.0 1.2 2.0 2.5 3.2 5.4 10.0 15.6 12.0
p21 induction (approximate) 1.0 1.0 1.2 1.4 2.5 5.0 10.0 15.0 12.0
Growth arrest nl G2 G2 G2 G1 G1 G1 G1 G1
G1/G0 (%) 48.9 34.2 28.2 23.6 42.4 64.3 77.3 75.0 70.0
S (%) 27.0 29.9 26.7 37.0 36.4 26.2 9.6 17.9 18.2
G2/M (%) 19.7 30.5 37.7 32.0 16.0 2.6 7.7 3.7 7.0
FIG. 7. Expression of wt p53 and p21/WAF1 is increased by treatment
of LCL with cisplatin in a dose-dependent manner. LCL were treated for
18 h with the indicated concentrations of cisplatin and then examined
sequentially for p53, p21/WAF1, and actin levels with stripping between
each step.
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Apoptosis was verified by morphological examination, by
demonstrating DNA fragmentation on gels, and by cell
cycle analysis (see below). The slight apparent decrease
in p53 levels at the highest cisplatin concentration likely
reflects the reduced numbers of cells present and pos-
sibly also degradation.
Induction of p21/WAF1 in the cisplatin-treated LCL
lagged behind the p53 induction curve at cisplatin con-
centrations of ,1.25 mg/ml but exactly mimicked the
levels of p53 induction when this reached ;5-fold over
endogenous levels (Table 1, Fig. 7). Cell cycle analyses of
the cells, however, revealed several unanticipated find-
ings (Table 1, Fig. 9). First, cells treated with the lowest
cisplatin concentrations (0.16–0.63 mg/ml), which yielded
;1.2- to 2.5-fold increases in p53 concentrations but little
increase in p21/WAF1 levels (maximum of 1.4-fold), were
growth arrested at the G2/M boundary (Table 1, Fig. 9).
This is clearly shown by the progressive decrease in
cells in G0/G1 and the progressive increase in cells in S
plus G2/M. These cells are not undergoing apoptosis
because subdiploid, apoptotic fragments are absent in
these samples in the cell cycle analyses (Fig. 9). Second,
LCL treated with intermediate cisplatin concentrations
(1.25–2.5 mg/ml), which yielded moderate increases in
p53 levels (;3.2- to 5.4-fold), and comparable increases
in p21/WAF1 levels, were growth arrested at the G1/S
boundary, as indicated by the increase in cells in G0/G1
and the decrease in the proportion of cells in S and
especially G2/M (Table 1, Fig. 9). The cell cycle analyses
revealed insignificant levels of apoptosis in these sam-
ples, as shown by the virtual absence of cells with a DNA
content of less that the diploid G0/G1 peak (Fig. 9).
Finally, LCL treated with $5.0 mg/ml cisplatin concentra-
tions, which exhibited $10-fold increases in p53 and
p21/WAF1, were not only growth arrested at the G1/S
boundary but also actively undergoing apoptosis, as
indicated by cell morphology and the increase in sub-
diploid fragments in the cell cycle studies (Table 1, Fig.
9). Apoptosis in LCL treated with 5, 10, and 20 mg/ml
cisplatin was confirmed by the use of gel electrophoresis
to demonstrate DNA fragmentation (Fig. 10).
DISCUSSION
Unlike other DNA tumor viruses, including SV40, ade-
novirus, and human papillomavirus, EBV gene products
do not directly inactivate the critical p53 regulator of cell
cycle progression and apoptosis. Rather, EBV, via the
actions of LMP1, prevents apoptosis triggered by ele-
vated levels of wt p53 (Okan et al., 1995). These actions
of LMP1 are probably mediated by bcl-2 or A20, or both,
two antiapoptotic proteins that are induced by the viral
latent protein (Henderson et al., 1991; Laherty et al., 1992;
Okan et al., 1995). LMP1, however, does not prevent
p53-induced cell cycle arrest at the G1/S boundary (Okan
et al., 1995). Thus EBV, via LMP1, interferes with certain
p53 functions but via different mechanisms than the
other DNA tumor viruses noted above. Curiously, LMP1
is also responsible for the induction of the increased
levels of transcriptionally active p53 that occur early
during EBV infection and persist thereafter in EBV-trans-
formed cells (Allday et al., 1995b; Chen and Cooper, 1996;
FIG. 8. Cisplatin treatment of LCL does not significantly change
LMP1 expression. LCL were treated for 18 h with the indicated con-
centrations of cisplatin and then examined for LMP1 expression in
Western blotting studies.
FIG. 9. Growth arrest and apoptosis induced by cisplatin treatment of
LCL. LCL were treated with the indicated concentrations of cisplatin for
18 h and then examined for cell cycle status by flow cytometry.
FIG. 10. Apoptosis induced by cisplatin treatment of LCL. LCL were
treated with the indicated concentrations of cisplatin for 18 h and then
examined for DNA fragmentation by gel electrophoresis.
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Szekely et al., 1995). The present studies were initiated to
determine why the increased levels of p53 that charac-
terize EBV infection do not induce either apoptosis or cell
cycle arrest, especially because overexpression of wt
p53 in LCL achieved by transfection or cisplatin treat-
ment and in BL by transfection led to growth arrest at the
G1/S boundary and to apoptosis (Allday et al., 1995a,
1995b; Okan et al., 1995). Although LMP1 could have
been responsible for abrogating the potential apoptotic
actions of increased p53 levels produced by EBV infec-
tion in our previous studies (Chen and Cooper, 1996),
because it has this property after overexpression in BL
as noted above (Okan et al., 1995), the LMP1 levels
prevailing in LCL were unable to block apoptosis trig-
gered by increased p53 levels induced by transfection or
cisplatin treatment (Allday et al., 1995a, 1995b).
We hypothesized that a critical relationship between
the levels of p53 and LMP1 determines whether EBV-
infected B cells respond to increased p53 levels with cell
cycle arrest and apoptosis to explain these various dis-
crepant findings. To evaluate this hypothesis, we exam-
ined cell cycle arrest and apoptosis in LCL expressing
increasing concentrations of p53 achieved by treating
the cells with increasing concentrations of the genotoxic
agent cisplatin; LMP1 levels were not significantly al-
tered by cisplatin. Apoptosis induced by DNA damage is
p53 dependent (Clarke et al., 1993; Kastan et al., 1991;
Lowe et al., 1993). These experiments were supple-
mented with studies in EBV-infected BL41 cells trans-
fected with ts mutant human p53 and with experiments in
LCL infected with recombinant adenoviruses expressing
either wt or the ts mutant p53. The results obtained here
not only confirm the hypothesis and thereby reconcile
the discrepant results obtained in the published studies
cited earlier but also reveal unanticipated complexities in
cell cycle regulation by p53.
A ;10-fold increase in p53 and p21/WAF1 concentra-
tions over endogenous levels in LCL resulted in cell
cycle arrest at the G1/S boundary and apoptosis. These
findings are consistent with published studies in LCL
induced to overexpress high levels of wt p53 by either
transfection or treatment with 10 mg/ml cisplatin (Allday
et al., 1995a, 1995b). Such p53 and p21/WAF1 levels are
;100-fold over those prevailing in uninfected human B
cells because EBV infection itself increases p53 ;10-
fold and triggers an even greater elevation in p21/WAF1
levels (Chen and Cooper, 1996). These levels of p53
apparently exceed those that can be regulated by the
levels of LMP1 in the cells. A lesser increase in p53 and
p21/WAF1 levels (;2.5- to 5-fold) also triggered cell cycle
arrest at the G1/S boundary but did not lead to apoptosis.
The LMP1 levels in these cells were apparently sufficient
to block p53-induced apoptosis. The studies in LCL in-
fected with recombinant adenovirus expressing either ts
mutant or wt p53 are entirely in accord with these find-
ings because the ;3.5- to 4-fold increase in p53 levels
produced cell cycle arrest at the G1/S boundary without
apoptosis. This is also true of the experiments in EBV-
infected BL41, where an estimated 3- to 4-fold increase in
wt p53 concentrations (compared with LCL levels) re-
sulted in G1/S cell cycle arrest without apoptosis.
Entirely unanticipated, however, was the finding that
small ;1.2- to 2.5-fold increases in p53 resulted in cell
cycle arrest at the G2/M boundary, again without apop-
tosis. Because these slight increases in p53 were not
accompanied by significant increases in p21/WAF1, it is
probable that cell cycle arrest at this checkpoint is inde-
pendent of the actions of this cell cycle regulatory pro-
tein. Some evidence has previously been obtained for
p53-induced cell cycle arrest at the G2/M boundary in
fibroblasts (Stewart et al., 1995), but such findings have
not been reported in B cells. The mechanism by which
p53 induces cell cycle arrest at the G2/M boundary may
be dependent on p53-mediated induction of the 14-3-3s
proteins (Hermeking et al., 1998).
A second finding derived from these studies is that
infection of BL41 with EBV prevents p53-induced apopto-
sis but not growth arrest at the G1/S boundary. Similarly,
LCL are growth arrested at either the G1/S or the G2/M
boundaries, depending on the p53 concentration. These
data indicate that none of the nine EBV latent proteins
expressed in EBV-infected BL41 cells or in LCL, both of
which exhibit type III latency, possess the ability to pre-
vent growth arrest at the G1/S or G2/M cell cycle check-
points induced by modest-to-moderate increases in lev-
els of cellular wt p53 over those found in LCL. LCL,
however, do not exhibit growth arrest. Therefore, the
10-fold increase in p53 levels that LCL exhibit relative to
uninfected B cells must not be sufficiently high to induce
growth arrest of the cells. Alternatively, EBV gene prod-
ucts may possess some ability to interfere with the G2/M
growth-arresting properties of modestly increased p53
levels, such as those prevailing in LCL. These aspects
are under investigation.
The most important conclusion emerging from these
studies is that p53-dependent effects on cell cycle reg-
ulation and apoptosis represent a continuum, with influ-
ences on cell cycle progression being evident with even
very small increases in p53 levels and with entirely
different effects being evident at low, intermediate, and
high p53 levels. Although these actions are clearly inter-
related with the growth-promoting effects of EBV latent
cycle proteins, they show that p53 actions are not all or
none but rather are dose dependent. They also are not
fundamentally different for EBV-infected and uninfected B
cells because the induction of proliferation of normal
EBV-uninfected cells by treatment with anti-CD40 plus
interleukin-4 increased cellular p53 levels to the same
extent as EBV infection (Allday et al., 1995b). Ligation of
the B cell antigen receptor (BCR) on EBV-uninfected B
cells also led to rapid increases in p53 and p21 (Wu et al.,
1998). In the latter study, transfection approaches
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showed that p53 and p21 were directly involved in the
signaling pathway leading to apoptosis after BCR liga-
tion. The concentrations of p53 that produce the various
described effects are likely to differ for various cell types,
including B cells, not only because of the different levels
of LMP1 expression in various LCL but also as a result of
other unknown cell-specific effects on proliferation and
growth regulation.
MATERIALS AND METHODS
Cells
BL41 is an EBV-negative BL cell line that bears mutant,
nonfunctional p53 (Farrell et al., 1991). EBV-infected BL41
was generated by incubation with EBV of the B95–8
strain, prepared as described previously (Nemerow and
Cooper, 1981). The LCL used in this study (JR) was also
generated by infection with B95–8 strain EBV. The cells
were maintained in RPMI 1640 medium with 10% fetal
calf serum.
Plasmids, transfections, recombinant adenovirus
preparations, and infection
Expression vectors containing the human ts p53 mu-
tant Val143Ala (pC53-SCX3) and wt human p53 (pC53-
SN3) were obtained from Bert Vogelstein (Baker et al.,
1990; Chen et al., 1992). BL41 cells were transfected by
electroporation (1 3 107 cells, 250 V, 960 mF, in a Gene
Pulser from BioRad, Richmond, CA). After culture for 3
days, the cells were selected with G418 at a concentra-
tion of 2 mg/ml for $2 weeks.
A recombinant adenovirus shuttle vector (pAd/RSV)
was generated by subcloning the RSV promoter-BGH
poly(A)1 expression cassette from the pRc/RSV vector
(InVitrogen, Carlsbad, CA) into the pE1sp1B (Microbix
Biosystems, Toronto, Canada) vector using BamHI and
BglII sites. The wt and mutant p53 cDNAs were inserted
into the HindIII–XbaI site of pAd/RSV. Then, 15 mg of each
construct and an equivalent amount of the adenovirus
packaging plasmid pJM17 (Microbix-Biosystems) were
cotransfected into the E1 transcomplementing cell line
293 using calcium phosphate. The recombinant adeno-
viruses, generated by homologous recombination, were
isolated by plaque formation on 293 cells as previously
reported (Huang et al., 1997). High-titered stocks (1–2 3
1012 virions/ml) of the recombinant adenoviruses were
grown in 293 cells and purified by density gradient ultra-
centrifugation. A control recombinant adenovirus lacking
a cDNA insert was constructed through the use of pAd/
RSV and pJM17. LCL were infected with 104 viral particles
per cell for 24 h, after which the cells were incubated at
32°C for an additional 48 h. Control b-Gal recombinant
virus was used for the determination of transfection ef-
ficiency. More than 90% of the cells were infected by the
recombinant viruses.
Growth assays
Cells were seeded at a density of 1 3 106/ml and
cultured at 37°C or 32°C. The cells were counted daily,
and viability was determined by trypan blue exclusion or
by the MTT assay (Chemicon, Temecula, CA).
Induction of varying levels of p53 and p21 in LCL
LCL were treated with varying concentrations of cis-
platin (Sigma Chemical, St. Louis, MO), obtained by the
addition of varying amounts of a 1.5 mg/ml stock solution
in PBS, to incrementally increase p53 and p21 levels.
Immunoblotting assays
These were performed as described (Chen and Coo-
per, 1996) using 5 3 105 cells per lane. The DO-1 anti-p53
monoclonal antibody (mAb) was obtained from Santa
Cruz Biotechnology (Santa Cruz, CA); the anti-p21/WAF1
and the bcl-2 mAbs were purchased from Oncogene
Research Products (Cambridge, MA). The PE2 anti-
EBNA2 and S12 anti-LMP1 mAbs have been previously
described (Chen and Cooper, 1996; Mann et al., 1985;
Young et al., 1989). The primary Abs were diluted with 5%
dry milk in PBS and incubated with the blots for either
1–2 h at room temperature or overnight at 4°C. Horse-
radish peroxidase-labeled goat anti-mouse IgG Ab
(Kirkegaard & Perry Laboratories, Gaithersburg, MD)
served as the second Ab, and signals were detected with
the ECL system (Amersham Life Sciences, Arlington
Heights, IL). After stripping (100 mM 2-mercaptoethanol,
2% SDS, 62.5 mM Tris–HCL, pH 6.7, at 70°C for 30 min),
the blots were reprobed with mAb to actin (clone C4, ICN
Biochemicals, Aurora, OH).
Densitometric analyses were carried out on a Per-
sonal Densitometer SI (Molecular Dynamics, Sunnyvale,
CA) using ImageQuant 4.2a software. Fold increases
were calculated by dividing pixel density units of the
various bands by the pixel density units obtained for the
controls.
Apoptosis assays
Apoptosis was detected after washing the cells in PBS
followed by staining with acridine orange (Sigma) and
visual examination under a fluorescent microscope. DNA
fragmentation was evaluated by a gel electrophoretic
method adapted from a published procedure (Sorenson
et al., 1990). In brief, cell pellets (1 3 106 cells), resus-
pended in buffer containing 10 mg/ml ribonuclease A,
15% Ficoll 70, and bromphenol blue, are loaded into
wells partially filled with 0.8% agarose containing 2%
SDS and 1.25 mg/ml proteinase K. Cell lysis begins in the
sample buffer and is completed during the initial elec-
trophoresis (20 V for 1 h). Electrophoresis is continued
(90 V) for 3 h, followed by rinsing of the gel in water,
overnight incubation in 100 ml of pH 8.0 TE buffer con-
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taining 20 mg/ml RNase A, and ethidium bromide stain-
ing.
Flow cytometric analyses of cell cycle progression
Cells were harvested; washed in ice-cold Tris-buffered
NaCl, pH 7.5, containing 5 mM EDTA (TSE); fixed by the
dropwise addition of 70% ethanol (220°C) with constant
gentle mixing; and stored overnight at 4°C before anal-
ysis. The fixed cells (2 3 106) were washed in TSE and
resuspended in 1 ml of a propidium iodide (PI) solution
composed of 0.025% PI in 0.1% sodium citrate, 0.01%
RNase, and 0.1% Triton X-100 in TSE (Stewart et al., 1995).
After $2 h at room temperature in the dark followed by
filtration through 41-mm Spectramesh (Spectrum, Laguna
Hills, CA), cell cycle status was determined by flow
cytometry on a FACSort using CELLQuest software (Bec-
ton Dickinson, San Jose, CA).
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